RECRUITING

Commercially Available Cannabis Products for Immune Support

Talk to us

Conditions

InfluenzaCOVID-19Common Cold

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This study will be a prospective observation of the use of commercially available hemp and cannabis products marketed for immune support.

Official Title

Commercially Available Cannabis (Hemp) Products for Immune Support: A Prospective Observational Study to Evaluate Safety and Effects

Quick Facts

Study Start:2023-11-01
Study Completion:2024-12-01
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05944705

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. 1. 18 years of age or older
  2. 2. Able to read and write in English
  3. 3. Active participants in the Pennsylvania medical marijuana program (for cannabis product users)
  4. 4. Currently experiencing one or more of the following symptoms due to an acute illness:
  5. 1. Fever or chills
  6. 2. Cough
  7. 3. Fatigue
  8. 4. Muscle or body aches
  9. 5. Headache
  10. 6. Sore throat
  11. 7. Congestion or runny nose
  12. 8. Nausea or Vomiting
  13. 9. Diarrhea
  14. 5. Agrees to consume their chosen hemp or cannabis product (for the cannabis arm) and to not use a different hemp or cannabis product through the duration of the study
  15. 6. Agrees to continue to abstain from using hemp or cannabis (for the non-cannabis/hemp using arm)
  16. 7. Must have smart phone or email and access to the internet
  17. 8. Be able to comply with study requirements including baseline, completion of electronic questionnaires, and study timeline parameters.
  1. 1. Women who are pregnant, breastfeeding, or planning to become pregnant.
  2. 2. Known allergy to any compounds in hemp or cannabis.
  3. 3. Endorses suicidal intent
  4. 4. Immunocompromised individuals
  5. 5. Unwilling or unable to comply with study procedures
  6. 6. Terminal Illness with life expectancy less than 1 year

Contacts and Locations

Study Contact

Ashley M Scherer, MS
CONTACT
3027503099
ashleys@centerisp.com

Principal Investigator

Philip Kim, MD
PRINCIPAL_INVESTIGATOR
Center For Interventional Pain and Spine

Study Locations (Sites)

Center for Interventional Pain and Spine
Bryn Mawr, Pennsylvania, 19010
United States

Collaborators and Investigators

Sponsor: Center For Interventional Pain and Spine

  • Philip Kim, MD, PRINCIPAL_INVESTIGATOR, Center For Interventional Pain and Spine

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-11-01
Study Completion Date2024-12-01

Study Record Updates

Study Start Date2023-11-01
Study Completion Date2024-12-01

Terms related to this study

Additional Relevant MeSH Terms

  • Influenza
  • COVID-19
  • Common Cold